PMID- 36119102
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20220926
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - New insights on the role of human leukocyte antigen complex in primary biliary 
      cholangitis.
PG  - 975115
LID - 10.3389/fimmu.2022.975115 [doi]
LID - 975115
AB  - Primary Biliary Cholangitis (PBC) is a rare autoimmune cholangiopathy. Genetic 
      studies have shown that the strongest statistical association with PBC has been 
      mapped in the human leukocyte antigen (HLA) locus, a highly polymorphic area that 
      mostly contribute to the genetic variance of the disease. Furthermore, PBC 
      presents high variability throughout different population groups, which may 
      explain the different geoepidemiology of the disease. A major role in defining 
      HLA genetic contribution has been given by genome-wide association studies (GWAS) 
      studies; more recently, new technologies have been developed to allow a deeper 
      understanding. The study of the altered peptides transcribed by genetic 
      alterations also allowed the development of novel therapeutic strategies in the 
      context of immunotolerance. This review summarizes what is known about the 
      immunogenetics of PBC with a focus on the HLA locus, the different distribution 
      of HLA alleles worldwide, and how HLA modifications are associated with the 
      pathogenesis of PBC. Novel therapeutic strategies are also outlined.
CI  - Copyright (c) 2022 Mulinacci, Palermo, Gerussi, Asselta, Gershwin and Invernizzi.
FAU - Mulinacci, Giacomo
AU  - Mulinacci G
AD  - Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of 
      Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
AD  - European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San 
      Gerardo Hospital, Monza, Italy.
FAU - Palermo, Andrea
AU  - Palermo A
AD  - Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of 
      Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
AD  - European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San 
      Gerardo Hospital, Monza, Italy.
FAU - Gerussi, Alessio
AU  - Gerussi A
AD  - Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of 
      Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
AD  - European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San 
      Gerardo Hospital, Monza, Italy.
FAU - Asselta, Rosanna
AU  - Asselta R
AD  - Department of Biomedical Sciences, Istituti di Ricovero e Cura a Carattere 
      Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Milan, Italy.
FAU - Gershwin, Merrill Eric
AU  - Gershwin ME
AD  - Division of Rheumatology, Allergy and Clinical Immunology, University of 
      California, Davis, Davis, CA, United States.
FAU - Invernizzi, Pietro
AU  - Invernizzi P
AD  - Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of 
      Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
AD  - European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San 
      Gerardo Hospital, Monza, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220831
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Genetic Predisposition to Disease
MH  - *Genome-Wide Association Study
MH  - HLA Antigens/genetics
MH  - Humans
MH  - *Liver Cirrhosis, Biliary/genetics
PMC - PMC9471323
OTO - NOTNLM
OT  - HLA haplotypes
OT  - genetics
OT  - human leukocyte antigens complex
OT  - immunotolerance
OT  - primary biliary cholangitis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/20 06:00
MHDA- 2022/09/21 06:00
PMCR- 2022/01/01
CRDT- 2022/09/19 04:22
PHST- 2022/06/21 00:00 [received]
PHST- 2022/08/11 00:00 [accepted]
PHST- 2022/09/19 04:22 [entrez]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.975115 [doi]
PST - epublish
SO  - Front Immunol. 2022 Aug 31;13:975115. doi: 10.3389/fimmu.2022.975115. eCollection 
      2022.